Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New strategy aims to boost lifesaving sickle cell drug use in nigeria

NCT ID NCT06318143

First seen May 22, 2026

Summary

This study tests ways to increase the use of hydroxyurea, a medicine that helps manage sickle cell disease, in Nigeria. Researchers will train healthcare workers and provide tools to help them prescribe and monitor the drug. The goal is to see if these strategies lead to more patients starting and staying on hydroxyurea, which can reduce pain episodes and other complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • University Of Abuja Teaching Hospital

    RECRUITING

    Abuja, Nigeria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hydroxyurea

What this could lead to

If successful, this could show how to get more people with sickle cell disease in Nigeria to take hydroxyurea, a proven treatment that reduces pain crises and complications.

What could go wrong

This is an implementation study, not a drug trial. It tests training and support for healthcare workers, so success depends on real-world adoption and may not directly improve health outcomes.

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.